Those agents are not working in NSCLC with wild-type EGFR overexpression, which is a reason that those agents fail in TNBC treatment even though molecular and cellular mechanisms are completely unclear [11–13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.